Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OB-24-02
- Development stage
- Preclinical
- Lead developer
- OCMS Bio
01
Overview
OB-24-02 is a preclinical therapeutic candidate developed by OCMS Bio for the treatment of human metabolism disorders. The drug targets the activin receptor type IIA and IIB (ActRIIA/B), which are members of the transforming growth factor-beta (TGF-beta) receptor family. These receptors play a significant role in regulating muscle mass, bone density, and metabolic homeostasis by binding ligands such as activins, myostatin, and growth differentiation factors. By modulating ActRIIA/B signaling, OB-24-02 is intended to address metabolic dysfunction, potentially through the enhancement of lean body mass or the regulation of energy expenditure.
02
Targets
ACVR2A (Activin receptor type 2A)ACVR2B (Activin receptor type IIB)
Beyond the preview
Go deeper on OB-24-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OB-24-02.